In a randomized trial, no woman who received twice-yearly lenacapavir acquired HIV; diagnostic challenges remain in those uncommon individuals who acquire HIV on cabotegravir.
Globally, about half of all HIV infections occur in women, yet women constitute only a small proportion of at-risk individuals taking pre-exposure prophylaxis (PrEP; NEJM JW Infect Dis Apr 8 2024 and JAMA 2024 Mar 19; 331:930). Now, in a manufacturer-sponsored study (PURPOSE-1), investigators evaluated whether twice-yearly lenacapavir (a long-acting HIV capsid inhibitor) is efficacious at preventing HIV.
About 5340 sexually active cisgender women in sub-Saharan Africa were randomized to receive twice-yearly subcutaneous lenacapavir, daily oral FTC-tenofovir alafenamide (FTC/TAF), or daily oral FTC-tenofovir disoproxil fumarate (FTC/TDF).
Key findings are as follows:
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)